Reaction

Ulcerative Keratitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,694 reports · 65 co-occurring drugs

As of the last recalculation, Ulcerative Keratitis appears in 2,694 FAERS reports alongside 65 co-occurring drug terms. The strongest observed disproportionality signal is PREDNISOLONE ACETATE (PRR 46.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Prednisolone Acetate	61	46.6	46.9
Moxifloxacin Hydrochloride	113	44.9	45.2
Moxifloxacin	57	31.9	32.0
Lifitegrast	59	28.5	28.6
Tobramycin Solution	38	24.8	24.9
Ampicillin	26	24.5	24.6
Ampicillin Sodium	26	24.5	24.6
Carboxymethylcellulose Sodium	29	24.1	24.2
Tobramycin Sulfate	38	24.0	24.1
Nevirapine	26	22.5	22.5
Erythromycin	52	21.8	21.9
Brinzolamide	24	21.5	21.6
Cenegermin-Bkbj	28	18.1	18.1
Dorzolamide Hydrochloride And Timolol Maleate	16	15.7	15.8
Erlotinib Hydrochloride	25	15.6	15.6
Minocycline	23	15.4	15.4
Erlotinib	19	15.3	15.3
Tobramycin	46	15.0	15.0
Atropine Sulfate	19	13.7	13.7
Atropine	14	13.1	13.1
Timolol	19	12.2	12.2
Brimonidine Tartrate	27	11.8	11.8
Timolol Maleate	15	11.8	11.8
Travoprost	12	10.8	10.8
Baricitinib	11	8.8	8.9
Bimatoprost	32	8.7	8.7
Latanoprost	49	7.6	7.7
Ranibizumab	26	7.6	7.6
Ganciclovir	10	7.6	7.6
Ado-Trastuzumab Emtansine	8	7.3	7.4
Ganciclovir Sodium	10	7.3	7.3
Adalimumab-Fkjp	39	6.6	6.6
Gentamicin	11	6.5	6.5
Aflibercept	26	6.5	6.5
Voriconazole Injection	18	6.4	6.4
Gentamicin Sulfate	13	6.4	6.4
Cetuximab	25	6.2	6.2
Adalimumab-Aaty	37	6.1	6.1
Tofacitinib Citrate	10	5.9	5.9
Doxycycline Hyclate	49	5.7	5.7
Diclofenac Sodium 1%	26	5.7	5.7
Diclofenac Sodium Topical	26	5.7	5.7
Diclofenac Sodium Topical Gel, 1%	26	5.7	5.7
Doxycycline	49	5.6	5.6
Diclofenac	61	5.6	5.6
Diclofenac Potassium, Film Coated	6	5.5	5.5
Diclofenac Potassium Tablets	6	5.5	5.5
Adalimumab-Adaz	37	5.5	5.5
Voriconazole	20	5.1	5.1
Valacyclovir	27	5.0	5.0
Valacyclovir Hydrochloride	45	5.0	5.0
Panitumumab	10	4.9	4.9
Tocilizumab	71	4.9	4.9
Diclofenac Potassium	6	4.3	4.3
Gefitinib	5	4.3	4.3
Trastuzumab	34	3.9	3.9
Bevacizumab	51	3.2	3.2
Golimumab	34	3.1	3.1
Trametinib	9	2.9	2.9
Faricimab	3	2.9	2.9
Isotretinoin	17	2.7	2.7
Nivolumab	33	2.7	2.7
Axicabtagene Ciloleucel	3	2.4	2.4
Osimertinib	9	2.2	2.2
Dupilumab	81	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.